

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
**FORM 12b-25**  
NOTIFICATION OF LATE FILING

(Check one): ☒ Form 10-K    ☐ Form 20-F    ☐ Form 11-K    ☐ Form 10-Q    ☐ Form 10-D    ☐ Form N-SAR  
☐ Form N-CSR

For the Ended: \_\_\_\_\_

- ☐ Transition Report on Form 10-K  
☐ Transition Report on Form 20-F  
☐ Transition Report on Form 11-K  
☐ Transition Report on Form 10-Q  
☐ Transition Report on Form N-SAR

For the Transition Period Ended: \_\_\_\_\_

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART 1 – REGISTRANT INFORMATION**

**Chemokine Therapeutics, Inc.**

Full Name of Registrant

Former Name if Applicable

**6190 Agronomy Road, Suite 405, University of British Columbia**

Address of Principal Executive Office (*Street and Number*)

**Vancouver, British Columbia, V6T 1Z3**

City, State and Zip Code

**PART II – RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)



- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR, or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

### PART III – NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Audit Committee of the Board of Directors is working with the company's management to obtain, compile and review certain accounting and financial information from a related party contract service provider with respect to potential cost adjustments that may be receivable or realizable by the company from such contract service provider. Obtaining and completing the review and analysis of the above-mentioned accounting and financial information and determining the appropriate Form 10-KSB disclosures related thereto will require additional time beyond the normal filing deadline for the company's 2006 Form 10-KSB. Consequently, the company is not able to timely file its 2006 Form 10-KSB without unreasonable effort or expense. The company expects to file the 2006 Form 10-KSB no later than the fifteenth calendar day after the prescribed due date.

### PART IV – OTHER INFORMATION

- (1) Name and telephone number of person to contact in regard to this notification

**Bashir Jaffer**

**(604)**

**822-0301**

(Name)

(Area Code)

(Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐

- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes ☐ No ☒

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

**Chemokine Therapeutics, Inc.**

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date \_\_\_\_\_

By \_\_\_\_\_

Bashir Jaffer

Chief Financial Officer